For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH. Benzoyl Peroxide Creamy Wash 4%

Similar documents
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL HYDROPHASE. Benzoyl Peroxide Cream IP

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory OILATUM EMOLLIENT. Light Liquid Paraffin Emollient

PRODUCT INFORMATION BREVOXYL CREAM

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory DERMOCALM LOTION. Calamine and Light Liquid Paraffin Lotion

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEDAX -5 LOTION. Permethrin Lotion 5% w/w

POLYTAR Plus Liquid PRODUCT INFORMATION. Polytar Plus Liquid medicated scalp cleanser, contains coal tar solution.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

DUAL ACTION LOGO. Quinoderm 10% / 0.5% w/w Cream Benzoyl Peroxide, hydrous / Potassium Hydroxyquinoline Sulfate

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BACTROBAN CREAM. Mupirocin Cream USP

SUMMARY OF PRODUCT CHARACTERISTICS

New Zealand Datasheet

4.3. Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

BACTROBAN OINTMENT. Mupirocin free acid. Bacterial skin infections, e.g. impetigo, folliculitis and furunculosis.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory T-BACT OINTMENT. Mupirocin Ointment IP

BACTROBAN CREAM QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

EPIDUO GEL PRODUCT INFORMATION

Each gram of mupirocin ointment contains 20 mg of mupirocin (2% w/w) as the active ingredient.

Package leaflet: Information for the user. ZORAC 0.05% gel ZORAC 0.1% gel. Tazarotene

New Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adapalene 0.1% topical gel

New Zealand Datasheet

The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water.

Package leaflet: Information for the patient. Epiduo 0.3% / 2.5% gel adapalene / benzoyl peroxide

PRODUCT INFORMATION DIFFERIN ADAPALENE 0.1% TOPICAL GEL

Package leaflet: Information for the user. Tactuo 0.1% / 2.5% gel Adapalene/Benzoyl Peroxide

CONSUMER MEDICINE INFORMATION

Reference ID: CONTRAINDICATIONS None. (4)

DAKTARIN. Miconazole, Miconazole nitrate CREAM, POWDER, SPRAY POWDER, LOTION, TINCTURE PRODUCT INFORMATION

ISOTREX GEL Isotretinoin 0.05% w/w

Rheumon Gel 1 g of gel contains 50 mg of etofenamate. For use in adults.

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. NIX Dermal Cream. Permethrin Cream, 5% w/w. Topical Scabicidal Agent

Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the

PACKAGE LEAFLET: INFORMATION FOR THE USER. Isotrex Gel isotretinoin 0.05% w/w

Package leaflet: Information for the user. Acnatac 10 mg/g mg/g gel clindamycin and tretinoin

PRODUCT MONOGRAPH. (clindamycin as clindamycin phosphate) clindamycin and benzoyl peroxide gel, 1% / 5%, w/w. (clindamycin as clindamycin phosphate)

Package leaflet: Information for the user Rogaine 50 mg/g, cutaneous foam. minoxidil

Package leaflet: Information for the patient. Duac Once Daily 10mg/g + 50mg/g Gel clindamycin + anhydrous benzoyl peroxide

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

ACETOCAUSTIN 0,5 ml, Cutaneous solution

MUPIROCIN OINTMENT 2% W/W TUBE New Zealand Data Sheet

Retin-A 0.05% w/w cream

New Zealand Data Sheet

WOMEN'S Regaine EXTRA STRENGTH

Prescribing Information. phisohex (hexachlorophene) Bottles of 150 ml, 450 ml. Pharmaceutical standard: USP. Antibacterial Skin Cleanser

MUPINASE Ointment/ Cream (Mupirocin)

PACKAGE LEAFLET: INFORMATION FOR THE USER. CURANAIL 5%, medicated nail lacquer Amorolfine

LUPIN LIMITED SAFETY DATA SHEET

PRODUCT INFORMATION DIFFERIN Adapalene 1mg/g TOPICAL CREAM

Item/Package Details Size Item Bottle ph Shelf Life 1.0 oz/29.6 ml 1101 Lucite Matte Silver Pump months

O N C E A DAY. In this leaflet FOR WOMEN

PATIENT INFORMATION LEAFLET. Timodine Cream

AVAGE (tazarotene) cream, 0.1%, for topical use Initial U.S. Approval: 1997

PACKAGE LEAFLET. EN Elastoplast Heat Plaster 11 mg January

Dermovate Scalp Application clobetasol propionate

Eumovate Cream clobetasone butyrate

Each gram of gel contains 10 mg (1%) clindamycin (as clindamycin phosphate) and 0.25 mg (0.025%) tretinoin.

Dermovate Ointment clobetasol propionate

TACTUPUMP. TACTUPUMP FORTE adapalene and benzoyl peroxide topical gel, 0.3%/2.5% w/w

Hydroform Cream 1% Hydrocortisone (microfine) 1% w/w and clioquinol 1% w/ w

Dermovate Ointment clobetasol propionate

Betnovate Scalp Application betamethasone valerate. 1 What Betnovate is and what it is used for. 2 What you need to know before you use Betnovate

Package leaflet: Information for the user. Trimovate Cream clobetasone 17-butyrate, calcium oxytetracycline and nystatin

MENTAX -TC (butenafine HCl) Cream, 1% Rx Only DESCRIPTION CLINICAL PHARMACOLOGY. Package Insert

Package Leaflet: Information for the User

Package leaflet: Information for the patient. Onytec 80 mg/g medicated nail lacquer For adults Ciclopirox

PRODUCT INFORMATION DALACIN T TOPICAL LOTION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. DALACIN T clindamycin 1% (10 mg/ml) (as phosphate) lotion.

Tinasolve Cream MATERIAL SAFETY DATA SHEET - EXTENDED. Tinasolve Tinea (Athlete s Foot) Cream - 25g IDENTIFICATION. PRODUCT: Tube SUPPLIER:

SAFETY DATA SHEETS. This SDS packet was issued with item: N/A

Hydrozole Cream Hydrocortisone (microfine) 1% w/w and clotrimazole 1% w/w

EpiCeram Topical therapeutic Skin Barrier Emulsion

Health Products Regulatory Authority IPAR. Public Assessment Report for a Medicinal Product for Human Use. Scientific discussion

ClobaDerm 500 micrograms/g Cream & Ointment (clobetasol propionate)

FULL PRESCRIBING INFORMATION

Children s Hospital Of Wisconsin

Daktacort 2% / 1% w/w cream

Your Manufacturer. of Pharmaceuticals. Licensing & Contract manufacturing

PACKAGE LEAFLET: INFORMATION FOR THE USER. CURANAIL 5%, medicated nail lacquer Amorolfine

TAZAROTENE- tazarotene cream G&W Laboratories, Inc

MATERIAL SAFETY DATA SHEET

PRODUCT MONOGRAPH. (erythromycin 2% w/w, ethyl alcohol 75% w/w, octinoxate 7.5% w/w, avobenzone 2% w/w) TOPICAL GEL WITH SUNSCREENS

clindamycin (as phosphate) 1% w/w and tretinoin 0.025% w/w; (klin-da-mye-sin fos-fate) and (tret- i-noin) CONSUMER MEDICINE INFORMATION

Package leaflet: Information for the user. Regaine for Men Extra Strength Scalp Foam 5% w/w cutaneous foam. Minoxidil

Dermovate Scalp Application clobetasol propionate

Percent (by weight) CAS Number <20%

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ClobaDerm 0.05% w/w Cream & Ointment (clobetasol propionate)

MATERIAL SAFETY DATA SHEET

European Cosmetic Regulation 1223/2009

scalp solution 5% w/v minoxidil cutaneous solution to be applied to the scalp

For Acne Vulgaris, A Topical Gel Treatment For Dermatologic Use

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. TRAVATAN Z Travoprost Ophthalmic Solution

BIACNA Topical Gel PRODUCT MONOGRAPH. (clindamycin phosphate and tretinoin) 1.2% w/w and 0.025% w/w. Acne Therapy

HOW TO USE. and make the most out of your CTCL treatment

URINE OUT. Safety Data Sheet SECTION 1. IDENTIFICATION SECTION 2. HAZARD IDENTIFICATION ESTEAM URINE OUT. Other Means of Identification

Issuing date: 04/17/2015 Revision date: 04/17/2015 Revision number: Identification of the substance/preparation and the company/undertaking

EMOLLIENTS. NEW 500g NEW. pump. Up to 37% Wider choice, greater savings! cost savings. without compromising on quality or patient care!

EFFECTIVE PRIMARY CARE MANAGEMENT OF ACNE VULGARIS

Product Name: Acne Medication Benzoyl Peroxide 10% Lotion Synonyms: None. Emergency telephone number: CHEMTREC

SAFETY DATA SHEET. Product Name: Licefreee! Everyday Shampoo Page 1 of 5 Tec Laboratories, Inc. Issue Date: 7/19/2016 Revision No.

Transcription:

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory BREVOXYL CREAMY WASH Benzoyl Peroxide Creamy Wash 4% QUALITATIVE AND QUANTITATIVE COMPOSITION Hydrous Benzoyl Peroxide IP equivalent to anhydrous Benzoyl Peroxide 4 % w/w PHARMACEUTICAL FORM Creamy (topical) wash. CLINICAL PARTICULARS Therapeutic Indications BREVOXYL CREAMY WASH is indicated for the treatment of mild to moderate acne vulgaris. Posology and Method of Administration For application to the skin. For external use only. Adults and adolescents The patient should wet the skin areas to be treated; apply BREVOXYL CREAMY WASH, gently massage for one to two minutes, rinse thoroughly and pat dry. Because excessive drying of the skin may occur, the patient should start with one application daily, then gradually increase to two or three times daily if needed. If excessive dryness or peeling occurs, frequency of application should be reduced or application temporarily interrupted, per physician instruction or patient tolerability. Maximum lesion reduction may be expected after approximately eight to twelve weeks of drug use. Continued use is normally required to maintain a clinical response. 1

Children Safety and effectiveness of topical benzoyl peroxide in children under the age of 12 has not been established. Elderly There are no specific recommendations for use in the elderly. Renal impairment No dosage adjustment is necessary. As there is very limited percutaneous absorption of benzoyl peroxide following topical application, renal impairment is not expected to result in systemic exposure of clinical significance. Hepatic impairment No dosage adjustment is necessary. As there is very limited percutaneous absorption of benzoyl peroxide following topical application, hepatic impairment is not expected to result in systemic exposure of clinical significance. Contraindications BREVOXYL CREAMY WASH is contraindicated in patients with known hypersensitivity to any of the ingredients. Special Warnings and Special Precautions for Use Contact with the eyes, eyelids, mouth, lips, other mucous membranes and broken skin should be avoided. During the first weeks of treatment, a sudden increase in peeling and reddening will occur in most patients and will normally subside in a day or two if treatment is temporarily discontinued. Patients should be advised that excessive application will not improve efficacy, but may increase the risk of skin irritation. As benzoyl peroxide may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sunlight should be avoided or minimised. When exposure to strong sunlight cannot be avoided, patients should be advised to use a sunscreen product and wear protective clothing. 2

The product may bleach hair and coloured or dyed fabrics. Avoid contact with hair, fabrics, furniture or carpeting. Interaction with Other Medicaments and Other Forms of Interaction Concomitant application of BREVOXYL CREAMY WASH with tretinoin, isotretinoin, and tazarotene should be avoided since it may reduce their efficacy and increase irritation. If combination treatment is required, the products should be applied at different times of the day (e.g., one in the morning and the other in the evening). Using BREVOXYL CREAMY WASH at the same time as topical sulfonamide-containing products may cause skin and facial hair to temporarily change colour (yellow/orange). Pregnancy and Lactation Fertility There are no data on the effect of topical benzoyl peroxide on fertility. Pregnancy There are limited data on the use of topical benzoyl peroxide in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Preclinical Safety Data). No effects during pregnancy are anticipated since systemic exposure to benzoyl peroxide is very limited. However, BREVOXYL CREAMY WASH should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus. Lactation Percutaneous absorption of benzoyl peroxide is very limited; however, it is not known whether benzoyl peroxide is excreted in human milk after topical application. BREVOXYL CREAMY WASH should be used during lactation only if the expected benefit justifies the potential risk to the infant. If used during lactation, BREVOXYL CREAMY WASH should not be applied to the breast area to avoid accidental ingestion by the infant. Effects on Ability to Drive and Use Machines No effects are anticipated based on the adverse reaction profile. 3

Undesirable Effects The following convention has been used for the classification of adverse reactions: Very common 1/10 Common 1/100 to <1/10 Uncommon 1/1000 to <1/100 Rare 1/10000 to <1/1000 Very rare <1/10000 Not known* (cannot be estimated from the available data). Clinical trial data Skin and subcutaneous tissue disorders Very Common: Common: Uncommon: Peeling, application site erythema. Dryness, pruritus and contact sensitisation reactions. Burning sensation. Post-marketing data The following post-marketing data come from published studies and the Company in-house adverse event reporting database. General Disorders and Administration Site Conditions Rare: Application site discoloration and application site reactions such as irritation and pain. Immune System Disorders Rare: Allergic reactions, including application site hypersensitivity and anaphylaxis. Skin and Subcutaneous Tissue Disorders Rare: Application site rash. Overdose Symptoms and signs Topically applied benzoyl peroxide is not generally absorbed in sufficient amounts to produce systemic effects. 4

Excessive application may result in severe irritation. In this event, discontinue use and wait until the skin has recovered. Treatment Cold compresses can provide relief from irritation due to excessive application. Accidental ingestion of topical benzoyl peroxide should be managed clinically or as recommended by the National Poisons Centre, where available. PHARMACOLOGICAL PROPERTIES Pharmacodynamic Properties Pharmacotherapeutic group: Benzoyl peroxide; ATC code: D10AE01. Mechanism of Action Benzoyl peroxide is a highly lipophilic oxidizing agent with bacteriocidal and keratolytic effects. Pharmacodynamic effects The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily attributable to its antibacterial activity, especially with respect to Propionibacterium acnes. The antibacterial activity of benzoyl peroxide is due to the release of active or free-radical oxygen capable of oxidising bacterial proteins. Benzoyl peroxide is also believed to be effective in the treatment of acne on account of its antiinflammatory and mild keratolytic properties. Pharmacokinetic Properties Absorption/Distribution/Metabolism Benzoyl peroxide is absorbed by the skin where it is metabolised to benzoic acid. Following topical application, less than 5% of the dose enters systemic circulation as benzoic acid. Elimination Benzoyl peroxide is excreted as benzoic acid in the urine. Special patient populations 5

Children Not relevant for this product. Elderly Not relevant for this product. Renal impairment See Posology and Method of Administration. Hepatic impairment See Posology and Method of Administration. Preclinical Safety Data Carcinogenesis/Mutagenesis Both the carcinogenicity and photocarcinogenicity of benzoyl peroxide have been extensively assessed in both mice and hamsters, by various routes of administration, in studies ranging from 42 to 100 weeks in duration. The overall conclusion is that benzoyl peroxide is considered to be generally recognized as a neither carcinogenic nor photocarcinogenic and safe in topical acne products at a concentration of 2.5% to 10%. The genotoxicity of benzoyl peroxide was extensively assessed in vitro and in vivo. While in a few in vitro studies benzoyl peroxide showed weak mutagenicity, the overall genotoxicity profile did not indicate significant biological relevance. Reproductive Toxicology Fertility and Pregnancy In a combined repeat- dose and reproduction/development toxicity study, benzoyl peroxide (250, 500 or 1,000 mg/kg/day) was administered orally to male rats for 29 days and female rats for 41-51 days. There were no treatment-related changes observed in the mating period, mating rate, conception rate, delivery rate, birth rate, pregnancy period, luteinization number, implantation number and the rate of losing embryos and foetuses after implantation. In pups, body weight was significantly decreased in the high-dose group. The no-observed-adverse-effect-level (NOAEL) for reproductive toxicities was considered to be 500 mg/kg/day. PHARMACEUTICAL PARTICULARS 6

List of Excipients Dimethyl isosorbide, Cetyl alcohol, Stearyl alcohol, Cetomacrogol, Light liquid paraffin, Citric acid anhydrous, Glycerine, Ammonium laureth sulphate, Cocamidopropyl betaine, Propylene glycol alginate, Purified Water. Incompatibilities No incompatibilities have been identified. Shelf life 24 months. The expiry date is indicated on the label and packaging. Special precautions for storage Store at a temperature not exceeding 25 C. Do not freeze. Keep out of reach of children. Nature and contents of container Tube in a carton. Instructions for Use / Handling For external use only. There are no other special requirements for use or handling of this product. For further information please contact: Stiefel India Private Ltd. Registered Office 401 & 402, A Wing, 4th Floor, Floral Deck Plaza, Opp. Rolta Bhavan, Central MIDC Road, Andheri ( E ). Mumbai- 400093. Trade marks are owned by or licensed to the GSK group of companies 7

Version: BRW/PI/IN/2017/01 dated 11 September 2017. Adapted from Benzoyl Peroxide GDS 03 dated 24 July 2014. 8